19d agoStocktwits NewsNEUTRAL 48Product/PR
IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push
Soon-Shiong teased a trial pairing Pluvicto’s targeted radiation with an IL-15-based immune treatment.
Archived explainer. For the current picture see today's IBRX page.
Why Is IMMUNITYBIO INC (IBRX) Stock Up Today?
By the Top Tier Newswire AI Desk · August 26, 2026 at 12:15 AM ET · reviewed against 1 wire stories
IMMUNITYBIO INC (IBRX) is up +8.05% in the latest session. Our newswire has captured 1 story on IBRX across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why IBRX stock is up today
ImmunityBio Inc stock rose 8.05% to $8.19 in early trading on Monday. The move followed a recent earnings report that beat estimates and new developments in the company’s cancer treatment pipeline. The stock has also seen a recent price rebound after a multi-day decline.
What Happened
ImmunityBio reported second-quarter adjusted earnings of $0.08 per share, exceeding the estimated loss of $0.09. Revenue for the period totaled $51.24 million, surpassing the projected $49.7 million. The company also received regulatory approval in the UAE for its lead drug for bladder cancer, marking the broadest approval to date. Additionally, the company’s ANKTIVA treatment received UAE approval for non-small cell lung cancer following a trial that showed a median overall survival of 14.6 months in checkpoint-refractory patients. These developments have sparked renewed investor interest.
The company’s founder has also teased a new trial combining Pluvicto’s targeted radiation with an IL-15-based immune treatment. This announcement has added to the momentum, as the stock extended a three-day losing streak before turning upward.
What The Data Shows
Over the last eight sessions, the stock has risen 5.9% from $7.51 to $7.95. The stock has traded between $1.95 and $12.43 over the past 52 weeks and currently has a market capitalization of $8.3 billion. The company remains unprofitable, with a trailing twelve-month earnings per share of -0.99, but revenue has grown by 192.9% in the same period. The stock has a beta of 0.13, indicating low volatility relative to the market. Recent insider transactions show five sales totaling $3.9 million in the last 90 days, with the most recent filing on July 6.
What To Watch
Investors should continue to monitor the company’s upcoming developments in its clinical trials and regulatory approvals. No earnings date is currently scheduled for the near future.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IBRX by the numbers
Last: $8.19Session: +8.05%7 sessions: +3.98%Coverage: 1 stories / 1 sourcesAI sentiment: 48/100 (mixed)Mkt cap: $8.3B52w: $1.95 to $12.43
The headlines behind the move
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IBRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IBRX move explainers: 2026-08-26 · 2026-08-25 · 2026-07-11